3755 Cote Ste-Catherine Rd, Suite B-425
Montreal Qc Canada H3t 1E2
Tel: 514- 340-8222 ext 22845
Fax:514-340-7931
email address
 
Administrative assistant:
Nadia Conte
Tel: 514- 340-8222 ext 22845

Dr Bernard J. Lapointe
 
Eric M. Flanders Chair in Palliative Medicine, McGill University
Director of Palliative Care, McGill University
Chief of the Marjorie & Gerald Bronfman Palliative Care Division, Jewish General Hospital
 
 
Dr Lapointe is a family physician by training, who became involved in caring for the terminally ill in the mid-1980s while working with persons living with AIDS / HIV. He currently leads the palliative care program at McGill University and at the Jewish General Hospital.
He is active in the search for novel analgesics, including his current work as co-principal investigator on the clinical evaluation of tetrodotoxin (a toxin found in the fugu fish) for cancer pain. He has also collaborated via the Clinical Research Unit of the Segal Cancer Centre on many multi-centre evaluations of innovative drugs for cancer pain. He is interested in the quality of life of people living with cancer and of their informal caregivers. He is currently collaborating with Dr. Robin Cohen on a major research initiative aimed at evaluating interventions in support of informal caregivers.
He is the past-President of the Palliative Care Association of Québec and of the Canadian Hospice Palliative Care Association (CHPCA). He is the Chair of the International Cooperation Committee of the CHPCA and is a member of the Board of the Canadian Society of Palliative Care Physicians. His contributions to the field of palliative care have been recognized with the 2010 Medal of Honour from the Réseau de soins palliatifs du Québec, the 2007 CHPCA Award of Excellence, and, in 2002, with Her Majesty Queen Elizabeth II’s Golden Jubilee Medal.
 
Recent publications
 
Hagen NA, Lapointe B, Ong-Lam M, Dubuc B, Walde D, Gagnon B, Love R, Goel R, Hawley P, Ho Ngoc A, du Souich P. A Multicentre open-label safety and efficacy study of Tetrodotoxin for cancer pain. Current Oncology, 2011, Volume 18, Number 3, 109-116.


Neil A. Hagen, Patrick du Souich, Bernard Lapointe, May Ong-Lam, David Walde, Robin Love, Anh Ho Ngoc and on behalf of the Canadian Study Group. Tetrodotoxin for moderate to severe cancer pain : A randomized, double blind, parallel design multicenter study. Journal of Pain and Symptom Management, 2008, Volume 35, Issue 4, 420-429.

Hagen NA, Fisher KM, Lapointe B, du Souich P, Chary S, Moulin D, Sellers E, NgocAH, on behalf of the Canadian Tetrodotoxin Study Group. An Open-Label, Multi-DoseEfficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe CancerRelated Pain. J Pain Symptom Manage. 2007; 34: 171-182
Snapshot


 
 
Important Links

 
Support research at the Lady Davis Institute - Jewish General Hospital